Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 289

1.

FLT3 ligand plasma levels have no impact on outcomes after allotransplant in acute leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Cytokine. 2019 Aug;120:85-87. doi: 10.1016/j.cyto.2019.04.015. Epub 2019 Apr 28.

PMID:
31035172
2.

Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid Malignancies.

Bouard L, Guillaume T, Peterlin P, Garnier A, Le Bourgeois A, Duquenne A, Mahe B, Dubruille V, Blin N, Touzeau C, Gastinne T, Le Bris Y, Lok A, Bonnet A, Le Gouill S, Moreau P, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2019 Mar 27. pii: S1083-8791(19)30209-5. doi: 10.1016/j.bbmt.2019.03.025. [Epub ahead of print]

PMID:
30928627
3.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study.

Trudel S, Tessoulin B, Jullien M, Blin N, Gastinne T, Mahé B, Dubruille V, Bonnet A, Lok A, Chevallier P, Peterlin P, Garnier A, Guillaume T, Le Bourgeois A, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1441-1447. doi: 10.1007/s00277-019-03649-3. Epub 2019 Mar 14.

PMID:
30874851
4.

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.

Jullien M, Trudel S, Tessoulin B, Mahé B, Dubruille V, Blin N, Gastinne T, Bonnet A, Lok A, Lebourgeois A, Peterlin P, Garnier A, Chevalier P, Guillaume T, Thomaré P, Le Gouill S, Moreau P, Touzeau C.

Ann Hematol. 2019 Jun;98(6):1435-1440. doi: 10.1007/s00277-019-03655-5. Epub 2019 Mar 14.

PMID:
30874850
5.

FLT3 ligand plasma levels in acute myeloid leukemia.

Peterlin P, Gaschet J, Guillaume T, Garnier A, Eveillard M, Le Bourgeois A, Cherel M, Debord C, Le Bris Y, Theisen O, Mahé B, Dubruille V, Godon C, Robillard N, Wuilleme S, Touzeau C, Gastinne T, Blin N, Lok A, Bonnet A, Le Gouill S, Moreau P, Béné MC, Chevallier P.

Haematologica. 2019 Jun;104(6):e240-e243. doi: 10.3324/haematol.2018.209460. Epub 2019 Jan 10. No abstract available.

6.

Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma Patients.

Bouard L, Bodet-Milin C, Bailly C, Guillaume T, Peterlin P, Garnier A, Bourgeois AL, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Bonnet A, Béné MC, Gouill SL, Moreau P, Kraeber-Bodéré F, Chevallier P.

Biol Blood Marrow Transplant. 2019 May;25(5):906-911. doi: 10.1016/j.bbmt.2018.11.019. Epub 2018 Nov 24.

PMID:
30481598
7.

Clofarabine-based reduced intensity conditioning regimen with peripheral blood stem cell graft and post-transplant cyclophosphamide in adults with myeloid malignancies.

Chevallier P, Peterlin P, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Touzeau C, Gastinne T, Lok A, Le Bris Y, Béné MC, Le Gouill S, Moreau P, Guillaume T.

Oncotarget. 2018 Sep 11;9(71):33528-33535. doi: 10.18632/oncotarget.26083. eCollection 2018 Sep 11.

8.

Genome-wide analysis of gene expression after one year of venom immunotherapy.

Karpinski P, Skiba P, Kosinska M, Rosiek-Biegus M, Królewicz E, Blin N, Meese E, Panaszek B, Nittner-Marszalska M, Sasiadek MM.

Immunol Lett. 2018 Dec;204:23-28. doi: 10.1016/j.imlet.2018.10.005. Epub 2018 Oct 10.

PMID:
30312636
9.

Limited long-term impact of insect venom immunotherapy on the micro-RNA landscape in whole blood.

Karpinski P, Kahraman M, Ludwig N, Skiba P, Kosinska M, Rosiek-Biegus M, Królewicz E, Panaszek B, Nittner-Marszalska M, Blin N, Keller A, Meese E, Malgorzata Sasiadek M.

J Investig Allergol Clin Immunol. 2018 Sep 5:0. doi: 10.18176/jiaci.0303. [Epub ahead of print]

10.

Subcutaneous rituximab given to patients for other indications than CD20+ B-cell lymphoma: A monocentric study of 20 cases.

Peterlin P, Guillaume T, Garnier A, Le Bourgeois A, Mahé B, Dubruille V, Blin N, Gallas P, Touzeau C, Gastinne T, Lok A, Thomare P, Chauvin C, Le Gouill S, Moreau P, Chevallier P.

Leuk Res Rep. 2018 Jan 17;9:16-17. doi: 10.1016/j.lrr.2018.01.002. eCollection 2018. No abstract available.

11.

A landscape of germ line mutations in a cohort of inherited bone marrow failure patients.

Bluteau O, Sebert M, Leblanc T, Peffault de Latour R, Quentin S, Lainey E, Hernandez L, Dalle JH, Sicre de Fontbrune F, Lengline E, Itzykson R, Clappier E, Boissel N, Vasquez N, Da Costa M, Masliah-Planchon J, Cuccuini W, Raimbault A, De Jaegere L, Adès L, Fenaux P, Maury S, Schmitt C, Muller M, Domenech C, Blin N, Bruno B, Pellier I, Hunault M, Blanche S, Petit A, Leverger G, Michel G, Bertrand Y, Baruchel A, Socié G, Soulier J.

Blood. 2018 Feb 15;131(7):717-732. doi: 10.1182/blood-2017-09-806489. Epub 2017 Nov 16.

12.

Carboplatin instead of cisplatin in combination with dexamethasone, high-dose cytarabine with or without rituximab (DHAC+/-R) is an effective treatment with low toxicity in Hodgkin's and non-Hodgkin's lymphomas.

Tessoulin B, Thomare P, Delande E, Moynard J, Gastinne T, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Boudreault JS, Perrin F, Lok A, Guillaume T, Garnier A, Peterlin P, Gallas P, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2017 Jun;96(6):943-950. doi: 10.1007/s00277-017-2981-2. Epub 2017 Apr 3.

PMID:
28374163
13.

Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?

Lestang E, Peterlin P, Le Bris Y, Dubruille V, Delaunay J, Godon C, Theisen O, Blin N, Mahe B, Gastinne T, Garnier A, Touzeau C, Voldoire M, Bene MC, Le Gouill S, Milpied N, Mohty M, Moreau P, Guillaume T, Chevallier P.

Eur J Haematol. 2017 Jul;99(1):60-69. doi: 10.1111/ejh.12891. Epub 2017 May 5.

PMID:
28370306
14.

Second-degree relative donors for T-replete haploidentical allogeneic stem cell transplantation with high-dose post-transplant cyclophosphamide: toward crossing the major HLA barrier.

Garnier A, Guillaume T, Peterlin P, Béné MC, Le Bris Y, Dubruille V, Mahé B, Gastinne T, Touzeau C, Blin N, Le Gouill S, Moreau P, Chevallier P.

Bone Marrow Transplant. 2017 Jul;52(7):1063-1064. doi: 10.1038/bmt.2017.60. Epub 2017 Apr 3. No abstract available.

PMID:
28368382
15.

Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14).

Touzeau C, Le Gouill S, Mahé B, Boudreault JS, Gastinne T, Blin N, Caillon H, Dousset C, Amiot M, Moreau P.

Haematologica. 2017 Mar;102(3):e112-e114. doi: 10.3324/haematol.2016.160408. Epub 2017 Jan 5. No abstract available.

16.

Late Complications and Quality of Life after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.

Clavert A, Peric Z, Brissot E, Malard F, Guillaume T, Delaunay J, Dubruille V, Le Gouill S, Mahe B, Gastinne T, Blin N, Harousseau JL, Moreau P, Milpied N, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2017 Jan;23(1):140-146. doi: 10.1016/j.bbmt.2016.10.011. Epub 2016 Oct 14.

17.

Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients.

Peterlin P, Guillaume T, Delaunay J, Mohty M, Garnier A, Mahe B, Dubruille V, Blin N, Voldoire M, Touzeau C, Chauvin C, Gastinne T, Béné MC, Le Gouill S, Moreau P, Chevallier P.

Semin Hematol. 2016 Jul;53(3):216-7. doi: 10.1053/j.seminhematol.2016.06.001. Epub 2016 Jun 18. No abstract available.

PMID:
27496314
18.

Rituximab maintenance after autologous stem cell transplantation prolongs response duration in non-naive rituximab follicular lymphoma patients: a single institution experience.

Bourcier J, Gastinne T, Leux C, Moreau A, Bossard C, Mahé B, Blin N, Dubruille V, Touzeau C, Voldoire M, Guillaume T, Peterlin P, Gallas P, Garnier A, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Chevallier P, Moreau P, Le Gouill S.

Ann Hematol. 2016 Aug;95(8):1287-93. doi: 10.1007/s00277-016-2705-z. Epub 2016 Jun 14.

PMID:
27297970
19.

Improvement of overall survival after allogeneic hematopoietic stem cell transplantation for children and adolescents: a three-decade experience of a single institution.

Brissot E, Rialland F, Cahu X, Strullu M, Corradini N, Thomas C, Blin N, Rialland X, Thebaud E, Chevallier P, Moreau P, Milpied N, Harousseau JL, Mechinaud F, Mohty M.

Bone Marrow Transplant. 2016 Feb;51(2):267-72. doi: 10.1038/bmt.2015.250. Epub 2015 Dec 7.

PMID:
26642337
20.

Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study.

Lassalle A, Thomaré P, Fronteau C, Mahé B, Jubé C, Blin N, Voldoire M, Dubruille V, Tessoulin B, Touzeau C, Chauvin C, Loirat M, Lok A, Bourcier J, Lestang E, Mocquet R, Barbarot V, Moreau P.

Ann Oncol. 2016 Feb;27(2):314-8. doi: 10.1093/annonc/mdv563. Epub 2015 Nov 16.

PMID:
26578729
21.

Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma.

Brissot E, Clavert A, Blin N, Roland V, Guillaume T, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Gaugler B, Moreau P, Mohty M.

Leukemia. 2015 Oct;29(10):2098-100. doi: 10.1038/leu.2015.64. Epub 2015 Mar 9. No abstract available.

PMID:
25748683
22.

Childhood acute lymphoblastic leukaemia and indicators of early immune stimulation: the Estelle study (SFCE).

Ajrouche R, Rudant J, Orsi L, Petit A, Baruchel A, Lambilliotte A, Gambart M, Michel G, Bertrand Y, Ducassou S, Gandemer V, Paillard C, Saumet L, Blin N, Hémon D, Clavel J.

Br J Cancer. 2015 Mar 17;112(6):1017-26. doi: 10.1038/bjc.2015.53.

23.

Electroencephalography as a clinical tool for diagnosing and monitoring attention deficit hyperactivity disorder: a cross-sectional study.

Helgadóttir H, Gudmundsson ÓÓ, Baldursson G, Magnússon P, Blin N, Brynjólfsdóttir B, Emilsdóttir Á, Gudmundsdóttir GB, Lorange M, Newman PK, Jóhannesson GH, Johnsen K.

BMJ Open. 2015 Jan 16;5(1):e005500. doi: 10.1136/bmjopen-2014-005500.

24.

A TMC1 (transmembrane channel-like 1) mutation (p.S320R) in a Polish family with hearing impairment.

Hassan MA, Shah AA, Szmida E, Smigiel R, Sasiadek MM, Pfister M, Blin N, Bress A.

J Appl Genet. 2015 Aug;56(3):311-6. doi: 10.1007/s13353-014-0263-4. Epub 2015 Jan 6.

PMID:
25560804
25.

Upfront allogeneic stem-cell transplantation for patients with nonlocalized untreated peripheral T-cell lymphoma: an intention-to-treat analysis from a single center.

Loirat M, Chevallier P, Leux C, Moreau A, Bossard C, Guillaume T, Gastinne T, Delaunay J, Blin N, Mahé B, Dubruille V, Augeul-Meunier K, Peterlin P, Maisonneuve H, Moreau P, Juge-Morineau N, Jardel H, Mohty M, Moreau P, Le Gouill S.

Ann Oncol. 2015 Feb;26(2):386-92. doi: 10.1093/annonc/mdu515. Epub 2014 Nov 12.

PMID:
25392158
26.

Lenalidomide as frontline therapy in polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes syndrome: a retrospective case series of eight patients.

Lestang E, Caristan A, Néel A, Graveleau J, Duhamel E, Masseau A, Connault J, Maisonneuve H, Le Gouill S, Blin N, Touzeau C, Moreau P, Hamidou M.

Leuk Lymphoma. 2015 Jun;56(6):1895-6. doi: 10.3109/10428194.2014.974595. Epub 2015 Jan 21. No abstract available.

PMID:
25347429
27.

Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.

Peterlin P, Delaunay J, Guillaume T, Gastinne T, Mahé B, Dubruille V, Blin N, Le Bourgeois A, Brissot E, Lodé L, Le Gouill S, Moreau P, Mohty M, Chevallier P.

Biol Blood Marrow Transplant. 2015 Jan;21(1):180-4. doi: 10.1016/j.bbmt.2014.08.018. Epub 2014 Aug 28.

28.

Congenital muscular dystrophy phenotype with neuromuscular spindles excess in a 5-year-old girl caused by HRAS mutation.

Bolocan A, Quijano-Roy S, Seferian AM, Baumann C, Allamand V, Richard P, Estournet B, Carlier R, Cavé H, Gartioux C, Blin N, Le Moing AG, Gidaro T, Germain DP, Fardeau M, Voit T, Servais L, Romero NB.

Neuromuscul Disord. 2014 Nov;24(11):993-8. doi: 10.1016/j.nmd.2014.06.437. Epub 2014 Jun 28.

PMID:
25070542
29.

Failure of bortezomib to cure acute antibody-mediated rejection in a non-compliant renal transplant patient.

Ryckewaert A, Allain-Launay E, Moreau A, Blancho G, Cesbron A, Blin N, Roussey G.

Pediatr Transplant. 2013 Sep;17(6):E131-6. doi: 10.1111/petr.12113. Epub 2013 Jul 9.

PMID:
23834525
30.

Atrioventricular septal defect in a case of Shwachman-Diamond syndrome.

Le Gloan L, Blin N, Langlard JM.

Cardiol Young. 2014 Jun;24(3):549-51. doi: 10.1017/S104795111300084X. Epub 2013 Jun 27.

PMID:
23803361
31.

Trefoil factor family member 2 (Tff2) KO mice are protected from high-fat diet-induced obesity.

De Giorgio MR, Yoshioka M, Riedl I, Moreault O, Cherizol RG, Shah AA, Blin N, Richard D, St-Amand J.

Obesity (Silver Spring). 2013 Jul;21(7):1389-95. doi: 10.1002/oby.20165. Epub 2013 Jun 11.

32.

Otoferlin couples to clathrin-mediated endocytosis in mature cochlear inner hair cells.

Duncker SV, Franz C, Kuhn S, Schulte U, Campanelli D, Brandt N, Hirt B, Fakler B, Blin N, Ruth P, Engel J, Marcotti W, Zimmermann U, Knipper M.

J Neurosci. 2013 May 29;33(22):9508-19. doi: 10.1523/JNEUROSCI.5689-12.2013.

33.

Comparison of outcomes after two standards-of-care reduced-intensity conditioning regimens and two different graft sources for allogeneic stem cell transplantation in adults with hematologic diseases: a single-center analysis.

Le Bourgeois A, Mohr C, Guillaume T, Delaunay J, Malard F, Loirat M, Peterlin P, Blin N, Dubruille V, Mahe B, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Lode L, Bene MC, Chevallier P.

Biol Blood Marrow Transplant. 2013 Jun;19(6):934-9. doi: 10.1016/j.bbmt.2013.03.009. Epub 2013 Mar 21.

34.

Prognostic impact of immune status and hematopoietic recovery before and after fludarabine, IV busulfan, and antithymocyte globulins (FB2 regimen) reduced-intensity conditioning regimen (RIC) allogeneic stem cell transplantation (allo-SCT).

Le Bourgeois A, Lestang E, Guillaume T, Delaunay J, Ayari S, Blin N, Clavert A, Tessoulin B, Dubruille V, Mahe B, Roland V, Gastinne T, Le Gouill S, Moreau P, Mohty M, Planche L, Chevallier P.

Eur J Haematol. 2013 Mar;90(3):177-86. doi: 10.1111/ejh.12049. Epub 2013 Jan 27.

PMID:
23301689
35.

Intermediate- and low-methylation epigenotypes do not correspond to CpG island methylator phenotype (low and -zero) in colorectal cancer.

Karpinski P, Walter M, Szmida E, Ramsey D, Misiak B, Kozlowska J, Bebenek M, Grzebieniak Z, Blin N, Laczmanski L, Sasiadek MM.

Cancer Epidemiol Biomarkers Prev. 2013 Feb;22(2):201-8. doi: 10.1158/1055-9965.EPI-12-0157. Epub 2012 Nov 21.

36.

Cardiomyopathies and congenital heart diseases in Shwachman-Diamond syndrome: a national survey.

Hauet Q, Beaupain B, Micheau M, Blayo M, Gandemer V, Gottrand F, Blin N, Fouyssac F, Lethor JP, Bellanné-Chantelot C, Bonnet D, Donadieu J.

Int J Cardiol. 2013 Aug 10;167(3):1048-50. doi: 10.1016/j.ijcard.2012.10.084. Epub 2012 Nov 17. No abstract available.

PMID:
23164595
37.

A set of specific miRNAs is connected with murine and human gastric cancer.

Shah AA, Leidinger P, Backes C, Keller A, Karpinski P, Sasiadek MM, Blin N, Meese E.

Genes Chromosomes Cancer. 2013 Mar;52(3):237-49. doi: 10.1002/gcc.22024. Epub 2012 Nov 2.

PMID:
23124995
38.

Safety and efficacy of rituximab in steroid-refractory chronic GVHD.

Clavert A, Chevallier P, Guillaume T, Delaunay J, Le Gouill S, Mahe B, Dubruille V, Gastinne T, Blin N, Moreau P, Mohty M.

Bone Marrow Transplant. 2013 May;48(5):734-6. doi: 10.1038/bmt.2012.203. Epub 2012 Oct 22. No abstract available.

PMID:
23085828
39.

Diagnostic accuracy of statistical pattern recognition of electroencephalogram registration in evaluation of cognitive impairment and dementia.

Snaedal J, Johannesson GH, Gudmundsson TE, Blin NP, Emilsdottir AL, Einarsson B, Johnsen K.

Dement Geriatr Cogn Disord. 2012;34(1):51-60. doi: 10.1159/000339996. Epub 2012 Aug 23.

PMID:
22922592
40.

Increased susceptibility to Yersinia enterocolitica Infection of Tff2 deficient mice.

Shah AA, Mihalj M, Ratkay I, Lubka-Pathak M, Balogh P, Klingel K, Bohn E, Blin N, Baus-Loncar M.

Cell Physiol Biochem. 2012;30(4):853-62. doi: 10.1159/000341463. Epub 2012 Aug 22.

41.

Is ASCT with TBI superior to ASCT without TBI in mantle cell lymphoma patients?

Peterlin P, Leux C, Gastinne T, Roland V, Mahé B, Dubruille V, Delaunay J, Chevallier P, Guillaume T, Blin N, Ayari S, Clavert A, Mohty M, Dousset C, Milpied N, Harousseau JL, Moreau P, Wuilleme S, Moreau A, Le Gouill S.

Transplantation. 2012 Aug 15;94(3):295-301.

PMID:
22797728
42.

Ergic2, a brain specific interacting partner of Otoferlin.

Żak M, Bress A, Brandt N, Franz C, Ruth P, Pfister M, Knipper M, Blin N.

Cell Physiol Biochem. 2012;29(5-6):941-8. doi: 10.1159/000188338. Epub 2012 May 11.

43.

New insights into the Tyrolean Iceman's origin and phenotype as inferred by whole-genome sequencing.

Keller A, Graefen A, Ball M, Matzas M, Boisguerin V, Maixner F, Leidinger P, Backes C, Khairat R, Forster M, Stade B, Franke A, Mayer J, Spangler J, McLaughlin S, Shah M, Lee C, Harkins TT, Sartori A, Moreno-Estrada A, Henn B, Sikora M, Semino O, Chiaroni J, Rootsi S, Myres NM, Cabrera VM, Underhill PA, Bustamante CD, Vigl EE, Samadelli M, Cipollini G, Haas J, Katus H, O'Connor BD, Carlson MR, Meder B, Blin N, Meese E, Pusch CM, Zink A.

Nat Commun. 2012 Feb 28;3:698. doi: 10.1038/ncomms1701.

PMID:
22426219
44.

Allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning regimen in children: a single-center experience.

Strullu M, Rialland F, Cahu X, Brissot E, Corradini N, Thomas C, Blin N, Rialland X, Méchinaud F, Mohty M.

Eur J Haematol. 2012 Jun;88(6):504-9. doi: 10.1111/j.1600-0609.2012.01776.x. Epub 2012 Mar 21.

PMID:
22372430
45.

Altered miRNA expression patterns in Tff2 knock-out mice correlate with cellular pathways of neoplastic development and caloric metabolism.

Shah AA, Leidinger P, Keller A, Wendschlag A, Meese E, Blin N.

Int J Mol Med. 2012 Apr;29(4):637-43. doi: 10.3892/ijmm.2012.881. Epub 2012 Jan 10.

46.

Quiz page February 2012: acute kidney injury in an adolescent with a family history of autoimmune disorders.

Allain-Launay E, Blin N, Moreau A, Roussey-Kesler G.

Am J Kidney Dis. 2012 Feb;59(2):A33-5. doi: 10.1053/j.ajkd.2011.08.038. No abstract available.

PMID:
22243955
47.

Efficacy of lenalidomide plus dexamethasone in patients older than 75 years with relapsed multiple myeloma.

Touzeau C, Blin N, Clavert A, Roland V, Loirat M, Tessoulin B, Le Gouill S, Planche L, Pennetier M, Mahe B, Mohty M, Malard F, Peterlin P, Dubruille V, Moreau P.

Leuk Lymphoma. 2012 Jul;53(7):1318-20. doi: 10.3109/10428194.2011.654116. Epub 2012 Jan 31.

PMID:
22211836
48.

Temporal expression pattern of Fkbp8 in rodent cochlea.

Zak M, Bress A, Pfister M, Blin N.

Cell Physiol Biochem. 2011;28(5):1023-30. doi: 10.1159/000335789. Epub 2011 Dec 15.

49.

Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity.

Guillaume T, Gaugler B, Chevallier P, Delaunay J, Ayari S, Clavert A, Rialland F, Le Gouill S, Blin N, Gastinne T, Mahé B, Dubruille V, Moreau P, Mohty M.

Bone Marrow Transplant. 2012 Aug;47(8):1112-7. doi: 10.1038/bmt.2011.231. Epub 2011 Nov 28.

PMID:
22120986
50.

Paraneoplastic cutaneous leukocytoclastic vasculitis disclosing multiple myeloma: a case report.

Peterlin P, Ponge T, Blin N, Moreau P, Hamidou M, Agard C.

Clin Lymphoma Myeloma Leuk. 2011 Aug;11(4):373-4. doi: 10.1016/j.clml.2011.03.034. Epub 2011 May 11.

PMID:
21729687

Supplemental Content

Support Center